As Australia’s life sciences industry accelerator, MTPConnect’s is backing Australian medical devices of the future through the BioMedTech Horizons Program. It’s a $45 million initiative of the Medical Research Future Fund to bring life-saving medical products from an idea to patients. 

It’s about nurturing medtech companies through the first valley of death and de-risking product development to increase the appeal to private investment.  

The first phase of the program supported 11 companies. And from 2019, a further three rounds awarded $30.3 million in funding to 38 companies. The good news is these latest projects have again captured the interest of investors, going on to secure at least $479 million of further flow-on and external investment. With the program wrapping up, we brought these innovators together for the BioMedTech Horizons Finale event in Melbourne and released an Impact report to share their innovation journeys. 

In this episode, we talk with BMTH program lead, Dr Gerard Gibbs and MTPConnect Chair the Honorable Jaala Pulford about the impacts of the program and the value of catalyst funding.

We also meet some of the awardees for an update on their promising innovations, including Robert Yearsley from ARIA Research, Anshul Dayal from Neuromersiv, Dr William Parr from 3DMorphic, Dr Ash Attia from Bionic Vision Technologies and Dr Cameron Ferris from Inventia.